Newman, SC, Bland, RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry
1991; 36: 239–45.
Nasrallah, HA, Meyer, JM, Goff, DC, McEvoy, JP, Davis, SM, Stroup, TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res
2006; 86: 15–22.
Barnes, TRE, Paton, C, Cavanagh, MR, Hancock, E, Taylor, D.
A UK audit of screening of metabolic side effects of antipsychotics in community patients. Schizophr Bull
2007; 33: 1397–403.
Fontaine, KR, Heo, M, Harrigan, EP, Shear, CL, Lakshminarayanan, M, Casey, DE, et al. Estimating the consequences of antipsychotic induced weight gain on health and mortality rates. Psychiatry Res
2001; 101: 277–88.
Taylor, D, Paton, C, Kerwin, R.
The Maudsely 2005–2006 Prescribing Guidelines, 8th edn.
Taylor & Francis, 2005.
Which atypical antipsychotic drug for schizophrenia?
Drug Ther Bull
2004; 42: 57–60.
Smellie, WSA. Testing pitfalls and summary of guidance in lipid management. BMJ
2006; 333: 83–6.
Smellie, WSA, Forth, J, Bareford, D.
Best practice in primary care pathology: review 3. J Clin Pathol
2006; 59: 1116.
Smellie, WSA, Forth, J, Ryder, S, Galloway, MJ, Wood, AC, Watson, ID. Best practice in primary care pathology: review 5. J Clin Pathol
2006; 59: 1229–37.
Scanlan, M, Houltram, B.
A Care Map for the Assessment and Management of Atypical Antipsychotic Side Effects. University College, Northampton, 2006.
Henderson, DC, Caligero, E, Gray, C.
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry
2000; 157: 975–81.
Henderson, DC, Daley, TB, Kunkel, L, Rodrigues-Scott, M, Koul, P, Hayden, D.
Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry
2004; 65: 686–9.
Lamberti, JS, Costea, GO, Olson, D, Crilly, JF, Maharaj, K, Tu, X, et al. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical – demographic correlates. J Clin Psychiatry
2005; 66: 900–906.
Lamberti, J, Olson, D, Crilly, J, Olivares, T, Williams, GC, Tu, X, et al. Prevalence of metabolic syndrome amongst patients receiving clozapine. Am J Psychiatry
2006; 163: 1273–6.
Ucok, A, Soygur, H, Atakli, C, Kuscu, K, Sartorius, N, Duman, ZC, et al. The impact of antistigma education on the attitudes of general practitioners regarding schizophrenia. Psychiatry Clin Neurosci
2006; 60: 439–43.